Clinical Trial Update: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ficlatuzumab plus erlotinib versus placebo plus erlotinib in previously untreated metastatic EGFR-mutated non-small cell lung cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Ficlatuzumab (ficlatuzumab)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-10-22